arrow
S

Steven A. Pergam

university of washington
H指数:42
被引数:7,976

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Phase 2 Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients

一项多中心、前瞻性、随机、双盲的II期研究,旨在评估尼他硝唑(Nitazoxanide)在治疗造血干细胞和实体器官移植受者诺如病毒感染中的临床和抗病毒疗效及安全性

2026-05-220
PRE
T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy

T细胞对流感疫苗接种的免疫反应:在自体嵌合抗原受体修饰T细胞治疗前后给药

2025-05-011
PRE
Isolation precautions associated with COVID-19 infections among immunocompromised populations: A multicenter study of nine National Cancer Institute-designated Comprehensive Cancer Centers

与免疫抑制人群COVID-19感染相关的隔离预防措施:一项针对九个国立癌症研究所指定的综合癌症中心的多中心研究

2025-02-010
PRE
Prevention and Treatment of Cancer-Related Infections, Version 3.2024

癌症相关感染的预防和治疗,3.2024版

2024-11-010
PRE
Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms

Cag-m/CLAG化疗治疗急性髓系白血病和高级别髓系肿瘤后侵袭性真菌感染

2023-06-303
OAAI
Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer

在患有血液系统癌症的门诊患者中,使用持续时间延长的尼马曲韦-利托那韦成功治疗持续性症状性冠状病毒19感染

2023-06-068
OAAI
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology
2023-01-0113
OAAI